{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:10:11Z","timestamp":1776798611410,"version":"3.51.2"},"reference-count":113,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["740678"],"award-info":[{"award-number":["740678"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Mexico"],"award-info":[{"award-number":["Mexico"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["09150181910040"],"award-info":[{"award-number":["09150181910040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/14740338.2020.1811229","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T07:53:30Z","timestamp":1597823610000},"page":"1237-1250","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["CGRP inhibitors for migraine prophylaxis: a safety review"],"prefix":"10.1080","volume":"19","author":[{"given":"Eduardo","family":"Rivera-Mancilla","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Villal\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Cinvestav-Coapa, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-126X","authenticated-orcid":false,"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.031286"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"cit0003","first-page":"976","volume":"954","author":"GBD2016 Headache Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230214"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2006.11.005"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.09.003"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.07.021"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.3.427"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1994.1405320.x"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00097-X"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f9626a"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444"},{"key":"cit0015","author":"de Vries T","year":"2020","journal-title":"Pharmacol Ther"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00404.x"},{"key":"cit0017","first-page":"285","volume":"9","author":"Goadsby PJ","year":"2010","journal-title":"Neurol"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315579627"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2008.11.007"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0533-9"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13110"},{"key":"cit0024","unstructured":"Amgen Inc. Erenumab (Aimovig\u2122): US prescribing information. [cited 2020 Apr 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0807-1"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1416097"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0979-y"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01929.x"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/304129a0"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/313054a0"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14075"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2013"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(85)90194-6"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412447701"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1987.126"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01523.x"},{"key":"cit0038","first-page":"264","volume":"1","author":"Russo AF","year":"2009","journal-title":"Mol Cell Pharmacol"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_187"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.01082.x"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00726.x"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398399"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410388435"},{"key":"cit0046","unstructured":"Allergan plc. Allergan receives U.S. FDA approval for UBRELVY\u2122 for the acute treatment of migraine with or without aura in adults. [cited 2020 Apr 24]. Available from: https:\/\/www.prnewswire.com\/news-releases\/allergan-receives-us-fda-approval-for-ubrelvy-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults-300979082.html"},{"key":"cit0047","unstructured":"Biohaven Pharmaceutical Company Holding Ltd. Biohaven\u2019s NURTEC\u2122 ODT (rimegepant) receives FDA approval for the acute treatment of migraine in adults. [cited 2020 Apr 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/biohavens-nurtec-odt-rimegepant-receives-fdaapproval-for-the-acute-treatment-of-migraine-in-adults-301013021.html"},{"key":"cit0048","unstructured":"NCT0372368. Efficacy and safety trial of rimegepant for migraine prevention in adults. [cited 2020 Apr 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732638"},{"key":"cit0049","unstructured":"NCT02848326. Efficacy, safety, and tolerability of multiple dosing regimens of oral atogepant (AGN-241689) in episodic migraine prevention. [cited 2020 Apr 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02848326"},{"key":"cit0050","unstructured":"Allergan plc. Allergan\u2019s oral CGRP receptor antagonist atogepant demonstrates robust efficacy and safety in episodic migraine prevention in a phase <\/Collab>2b\/3 clinical trial. [cited 2020 10 Apr]. Available from: https:\/\/www.prnewswire.com\/news-releases\/allergans-oral-cgrp-receptor-antagonist-atogepantdemonstrates-robust-efficacy-and-safety-in-episodic-migraine-prevention-in-a-phase-2b3-clinical-trial-300663770.html"},{"key":"cit0051","author":"Martelletti P","year":"2020","journal-title":"Drugs Future"},{"key":"cit0052","unstructured":"NCT03855137. Efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine. [cited 2020 Apr 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03855137"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"cit0056","unstructured":"Biohaven Pharmaceutical Company Holding Ltd. Biohaven delivers positive phase 3 results with rimegepant zydis\u00ae orally dissolving tablet (ODT): rapid and lasting benefit for the acute treatment of migraine. [cited 2020 Apr 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/biohaven-delivers-positivephase-3-results-with-rimegepant-zydis-orally-dissolving-tablet-odt-rapid-and-lasting-benefit-forthe-acute-treatment-of-migraine-300758762.html"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419884943"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01134-1"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"cit0061","unstructured":"Novartis. Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention. [cited 2020 Apr 11] Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention"},{"key":"cit0062","unstructured":"Novartis. Novartis receives European licence for Aimovig\u00ae?(erenumab), the first treatment designed specifically for the prevention of migraine. [cited 2020 Apr 11]. Available from: https:\/\/www.novartis.co.uk\/news\/media-releases\/novartis-receives-european-licence-aimovigrverenumab-first-treatment-designed"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419854082"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420912726"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419863027"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.286"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.197"},{"key":"cit0072","unstructured":"Lundbeck H, A S H. Lundbeck A\/S. FDA approves Lundbeck\u2019s Vyepti\u2122 (eptinezumab-jjmr) \u2013 the first and only intravenous preventive treatment for migraine.[cited 2020 Apr 10]. Available from: https:\/\/investor.lundbeck.com\/news-releases\/newsrelease-details\/fda-approves-lundbecks-vyeptitm-eptinezumab-jjmr-first-and-only\/"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70209-1"},{"key":"cit0074","author":"Ashina M","year":"2020","journal-title":"Cephalalgia"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413517775"},{"key":"cit0077","unstructured":"U.S. Food and Drug Administration. Drug approval package: ajovy (fremanezumab-vfrm). Teva Pharmaceuticals USA, Inc; [cited 2020 Apr 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761089Orig1s000TOC.cfm"},{"key":"cit0078","unstructured":"Teva Pharmaceutical Industries Ltd. Teva\u2019s AJOVY\u00ae receives EU approval offering patients the first and only anti-CGRP treatment with both quarterly and monthly dosing for the prophylaxis of migraine in adults.[cited 2020 Apr 14] Available from: https:\/\/www.tevapharm.com\/news-and-media\/latest-news\/tevas-ajovy-receives-eu-approval-offering-patients-the-first-and-only-anti-cgrp-treatment-with-both-qua\/"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00245-8"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/head.13156"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414527646"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1635452"},{"key":"cit0086","unstructured":"Eli Lilly and Company. Lilly\u2019s Emgality\u2122 (galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of migraine in adults. [cited 2020 Apr 20] Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval"},{"key":"cit0087","unstructured":"European Medicines Agency. Emgality (galcanezumab). [cited 2020 Apr 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emgality"},{"key":"cit0088","unstructured":"European Medicines Agency. Emgality (galcanezumab). [cited 2020 Apr 28]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/emgality"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1193-2"},{"key":"cit0094","author":"Denekas T","journal-title":"Br J Pharmacol. 2006;148:536\u2013543"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90645-X"},{"key":"cit0096","first-page":"657","volume":"286","author":"Reinshagen M","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(93)90051-B"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.002"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1111\/head.13316"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/head.13402"},{"key":"cit0101","author":"Mulder IA","year":"2020","journal-title":"Ann Neurol"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2016.11.004"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02517"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(98)00025-3"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.07.006"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.02.024"},{"key":"cit0107","unstructured":"IUPHAR\/BPS Guide to PHARMACOLOGY. Calcitonin receptor. [cited 2020 May 18]. Available from: https:\/\/www.guidetopharmacology.org\/GRAC\/FamilyDisplayForward?familyId=11"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01695.x"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.11.014"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0619-8"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30126-6"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2020.1811229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:30:45Z","timestamp":1644946245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2020.1811229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/14740338.2020.1811229"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2020.1811229","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}